Integrated LC-MS/MS profiling, network pharmacology and experimental validation reveal inhibition of the IL-6/JAK2/STAT3 pathway by Shenqi Compound in comorbid chronic pancreatitis and type 2 diabetes mellitus.
ETHNOPHARMACOLOGICAL RELEVANCE Shenqi Compound (SQC) is effective in treating type 2 diabetes mellitus (T2DM). Preliminary clinical observations suggest that it may also improve pancreatic fibrosis in T2DM patients with comorbid chronic pancreatitis (CP), which prompted this mechanistic study. AIMS OF THE STUDY This...